Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German Research
Abstract The innovative strength of research performance is often measured in terms of inputs such as research funds or outputs such as patent applications. We present a novel indicator of pharmaceutical innovativeness that focuses on global medical breakthroughs and associated patents. According to...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
Sciendo
2021-08-01
|
| Series: | Wirtschaftsdienst |
| Online Access: | https://doi.org/10.1007/s10273-021-2985-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832570107368308736 |
|---|---|
| author | Andreas Eckert Wolfgang Maennig |
| author_facet | Andreas Eckert Wolfgang Maennig |
| author_sort | Andreas Eckert |
| collection | DOAJ |
| description | Abstract The innovative strength of research performance is often measured in terms of inputs such as research funds or outputs such as patent applications. We present a novel indicator of pharmaceutical innovativeness that focuses on global medical breakthroughs and associated patents. According to this indicator, US companies account for 55 % of global medical breakthroughs from 2010 to 2019, and their German competitors account for about 9 %. In terms of underlying anchor patents, the dominance of the US is even larger, at 62 %, while only 7 % of anchor patents come from Germany. US universities hold 3.8 % of all anchor patents; German universities hold none. The weakness of German universities cannot be compensated by German non-university research institutes. |
| format | Article |
| id | doaj-art-ec4fa074f7bb42229c3a601fbae23c92 |
| institution | Kabale University |
| issn | 0043-6275 1613-978X |
| language | deu |
| publishDate | 2021-08-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Wirtschaftsdienst |
| spelling | doaj-art-ec4fa074f7bb42229c3a601fbae23c922025-02-02T17:10:17ZdeuSciendoWirtschaftsdienst0043-62751613-978X2021-08-01101865265910.1007/s10273-021-2985-3Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German ResearchAndreas Eckert0Wolfgang Maennig1Frühphasenfinanzierung GmbH, Eckert Wagniskapital undFakultät für Wirtschafts- und Sozialwissenschaften, Universität HamburgAbstract The innovative strength of research performance is often measured in terms of inputs such as research funds or outputs such as patent applications. We present a novel indicator of pharmaceutical innovativeness that focuses on global medical breakthroughs and associated patents. According to this indicator, US companies account for 55 % of global medical breakthroughs from 2010 to 2019, and their German competitors account for about 9 %. In terms of underlying anchor patents, the dominance of the US is even larger, at 62 %, while only 7 % of anchor patents come from Germany. US universities hold 3.8 % of all anchor patents; German universities hold none. The weakness of German universities cannot be compensated by German non-university research institutes.https://doi.org/10.1007/s10273-021-2985-3 |
| spellingShingle | Andreas Eckert Wolfgang Maennig Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German Research Wirtschaftsdienst |
| title | Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German Research |
| title_full | Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German Research |
| title_fullStr | Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German Research |
| title_full_unstemmed | Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German Research |
| title_short | Pharmaceutical Innovations: Superior Position of the USA and Weaknesses of German Research |
| title_sort | pharmaceutical innovations superior position of the usa and weaknesses of german research |
| url | https://doi.org/10.1007/s10273-021-2985-3 |
| work_keys_str_mv | AT andreaseckert pharmaceuticalinnovationssuperiorpositionoftheusaandweaknessesofgermanresearch AT wolfgangmaennig pharmaceuticalinnovationssuperiorpositionoftheusaandweaknessesofgermanresearch |